Logo

Paradigm Providing Genomic Testing for Pharmatech's Cancer Registry

Aug 05, 2014 | staff reporter

NEW YORK (GenomeWeb) – Paradigm today announced it has initiated genomic testing for Pharmatech's AccessPPM Cancer Registry.

Non-profit diagnostics shop Paradigm offers a next-generation sequencing-based cancer test called PCDx that sequences both DNA and RNA. It will provide the test for patients that are enrolled in Pharmatech's AccessPPM, a cancer registry that collects electronic medical record data and genomic information to match cancer patients with targeted clinical trials.

"We believe AccessPPM will change the way today's oncology patient accesses clinical trials and will help pharmaceutical companies identify patients that are truly interested in research," Pharmatech CEO Rob Bohacs said in a statement.

Financial and other terms of the deal were not disclosed.

Filed under

Business News
Clinical Sequencing
Sequencing
Diagnostics
Cancer
collaboration
Next-Generation Sequencing
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.